<?xml version="1.0" encoding="UTF-8"?>
<results title="testTrace">
 <result pre="U.S. Food and Drug Administration (FDA) approved drug for the" exact="treatment" post="of patients suffering from severe symptoms of COVID-19 affirms"/>
 <result pre="diseases that might develop in the future. Similar to the" exact="treatment" post="of influenza, we would benefit from multiprong defense tactics"/>
 <result pre="viral particle and play additional functional roles during infection. Viral" exact="infection" post="begins with an interaction between the viral spike glycoprotein"/>
 <result pre="(to help stimulate the immune system); and hydroxychloroquine (this last" exact="treatment" post="has currently been paused). The FDA-approved COVID-19 drug, remdesivir,"/>
 <result pre="inhibition of viral replication is a viable strategy for the" exact="treatment" post="of COVID-19. Importantly, it takes more than a single"/>
 <result pre="1), exhibit nanomolar antiviral activity and are selective for HSV" exact="infection" post="in mouse models. The clinically used amenamevir (2), another"/>
 <result pre="compound 5, have EC50 values of âˆ¼10 uM against SARS-CoV-1" exact="infection" post="in cell culture with no associated cytotoxicity.17 Structural information"/>
 <result pre="lipidated peptide fusion inhibitors have been designed that inhibit pseudovirus" exact="infection" post="of cells with IC50 values in the single-digit nanomolar"/>
 <result pre="HaebichD.; LockhoffO.; RÃ¼bsamen-WaigmannH.New helicase-primase inhibitors as drug candidates for the" exact="treatment" post="of herpes simplex disease. Nat. Med.2002, 8 (4), 392â€&quot;8."/>
 <result pre="QinC.; SunF.; ShiZ.; ZhuY.; JiangS.; LuL.Inhibition of SARS-CoV-2 (previously 2019-nCoV)" exact="infection" post="by a highly potent pan-coronavirus fusion inhibitor targeting its"/>
</results>
